Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...